Resona Asset Management Co. Ltd. Makes New $401,000 Investment in Krystal Biotech, Inc. $KRYS

Resona Asset Management Co. Ltd. acquired a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,917 shares of the company’s stock, valued at approximately $401,000.

Several other hedge funds and other institutional investors have also modified their holdings of KRYS. Brooklyn Investment Group grew its stake in Krystal Biotech by 291.7% in the 1st quarter. Brooklyn Investment Group now owns 141 shares of the company’s stock valued at $25,000 after buying an additional 105 shares during the last quarter. Twin Tree Management LP bought a new stake in shares of Krystal Biotech during the first quarter worth approximately $29,000. Hantz Financial Services Inc. boosted its holdings in shares of Krystal Biotech by 8,950.0% during the second quarter. Hantz Financial Services Inc. now owns 181 shares of the company’s stock worth $25,000 after acquiring an additional 179 shares during the period. First Horizon Advisors Inc. grew its position in shares of Krystal Biotech by 212.8% in the second quarter. First Horizon Advisors Inc. now owns 244 shares of the company’s stock valued at $34,000 after purchasing an additional 166 shares during the last quarter. Finally, Smartleaf Asset Management LLC increased its stake in shares of Krystal Biotech by 128.3% during the first quarter. Smartleaf Asset Management LLC now owns 315 shares of the company’s stock worth $58,000 after purchasing an additional 177 shares during the period. Institutional investors own 86.29% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Bank of America boosted their price target on Krystal Biotech from $182.00 to $255.00 and gave the company a “buy” rating in a research note on Friday, October 17th. Citigroup upped their price target on shares of Krystal Biotech from $166.00 to $198.00 and gave the company a “neutral” rating in a research note on Tuesday, November 4th. HC Wainwright reaffirmed a “buy” rating and set a $240.00 price target on shares of Krystal Biotech in a research report on Monday, September 15th. Guggenheim set a $224.00 price objective on shares of Krystal Biotech and gave the stock a “buy” rating in a research note on Friday, October 17th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Krystal Biotech in a research report on Wednesday, October 8th. Six analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, Krystal Biotech presently has a consensus rating of “Moderate Buy” and a consensus target price of $228.14.

Krystal Biotech Stock Up 1.7%

KRYS stock opened at $203.00 on Wednesday. Krystal Biotech, Inc. has a 52 week low of $122.80 and a 52 week high of $212.98. The business has a 50-day simple moving average of $176.67 and a 200 day simple moving average of $154.33. The company has a market cap of $5.89 billion, a PE ratio of 30.43 and a beta of 0.65.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, November 3rd. The company reported $2.66 EPS for the quarter, beating the consensus estimate of $1.12 by $1.54. Krystal Biotech had a net margin of 53.30% and a return on equity of 19.36%. The company had revenue of $97.80 million during the quarter, compared to analysts’ expectations of $93.72 million. On average, analysts anticipate that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).